PTEN loss detection in prostate cancer: Comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort

Tamara Lotan, Asmus Heumann, Sebastian Dwertmann Rico, Jessica Hicks, Kristen Lecksell, Christina Koop, Guido Sauter, Thorsten Schlomm, Ronald Simon

Research output: Contribution to journalArticle

Abstract

PTEN deletion is an established prognostic biomarker in prostate cancer. We compared PTEN immunohistochemistry (IHC) and PTEN fluorescence in situ hybridization (FISH) in the largest existing radical prostatectomy cohort with clinical follow-up data. There was high concordance between IHC and FISH: 93% (3098/3330) of tumors with intact PTEN IHC showed absence of PTEN gene deletion and 66% (720/1087) of cases with PTEN protein loss by IHC showed PTEN gene deletion by FISH. 84% (447/533) of cases with PTEN homozygous gene deletion had PTEN protein loss by IHC. PTEN loss by IHC was associated with reduced PSA recurrence-free survival (RFS) in multivariable models (HR=1.3; 95% CI: 1.16-1.47). Among cases with either PTEN deletion or absence of PTEN deletion by FISH, PTEN loss by IHC was strongly associated with reduced RFS on univariable analysis (p=0.0005 and p < 0.0001 respectively). Among cases with intact PTEN by IHC, homozygous (p=0.04) but not heterozygous (p=0.10) PTEN gene deletion was weakly associated with reduced RFS. Among cases with PTEN loss by IHC, both homozygous (p=0.0044) and heterozygous (p=0.0017) PTEN gene deletion were associated with reduced RFS. These data support the utility of PTEN IHC and PTEN FISH as complementary screening tools for PTEN loss in prostate cancer.

Original languageEnglish (US)
Pages (from-to)65566-65576
Number of pages11
JournalOncotarget
Volume8
Issue number39
DOIs
StatePublished - 2017

Fingerprint

Prostatectomy
Fluorescence In Situ Hybridization
Prostatic Neoplasms
Immunohistochemistry
Gene Deletion
PTEN Phosphohydrolase
Recurrence
Biomarkers

Keywords

  • Biomarker
  • Fluorescence in situ hybridization
  • Immunohistochemistry
  • Prostatic carcinoma
  • PTEN

ASJC Scopus subject areas

  • Oncology

Cite this

PTEN loss detection in prostate cancer : Comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. / Lotan, Tamara; Heumann, Asmus; Rico, Sebastian Dwertmann; Hicks, Jessica; Lecksell, Kristen; Koop, Christina; Sauter, Guido; Schlomm, Thorsten; Simon, Ronald.

In: Oncotarget, Vol. 8, No. 39, 2017, p. 65566-65576.

Research output: Contribution to journalArticle

Lotan, T, Heumann, A, Rico, SD, Hicks, J, Lecksell, K, Koop, C, Sauter, G, Schlomm, T & Simon, R 2017, 'PTEN loss detection in prostate cancer: Comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort', Oncotarget, vol. 8, no. 39, pp. 65566-65576. https://doi.org/10.18632/oncotarget.19217
Lotan, Tamara ; Heumann, Asmus ; Rico, Sebastian Dwertmann ; Hicks, Jessica ; Lecksell, Kristen ; Koop, Christina ; Sauter, Guido ; Schlomm, Thorsten ; Simon, Ronald. / PTEN loss detection in prostate cancer : Comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. In: Oncotarget. 2017 ; Vol. 8, No. 39. pp. 65566-65576.
@article{3529961678df4674851316dc48915f69,
title = "PTEN loss detection in prostate cancer: Comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort",
abstract = "PTEN deletion is an established prognostic biomarker in prostate cancer. We compared PTEN immunohistochemistry (IHC) and PTEN fluorescence in situ hybridization (FISH) in the largest existing radical prostatectomy cohort with clinical follow-up data. There was high concordance between IHC and FISH: 93{\%} (3098/3330) of tumors with intact PTEN IHC showed absence of PTEN gene deletion and 66{\%} (720/1087) of cases with PTEN protein loss by IHC showed PTEN gene deletion by FISH. 84{\%} (447/533) of cases with PTEN homozygous gene deletion had PTEN protein loss by IHC. PTEN loss by IHC was associated with reduced PSA recurrence-free survival (RFS) in multivariable models (HR=1.3; 95{\%} CI: 1.16-1.47). Among cases with either PTEN deletion or absence of PTEN deletion by FISH, PTEN loss by IHC was strongly associated with reduced RFS on univariable analysis (p=0.0005 and p < 0.0001 respectively). Among cases with intact PTEN by IHC, homozygous (p=0.04) but not heterozygous (p=0.10) PTEN gene deletion was weakly associated with reduced RFS. Among cases with PTEN loss by IHC, both homozygous (p=0.0044) and heterozygous (p=0.0017) PTEN gene deletion were associated with reduced RFS. These data support the utility of PTEN IHC and PTEN FISH as complementary screening tools for PTEN loss in prostate cancer.",
keywords = "Biomarker, Fluorescence in situ hybridization, Immunohistochemistry, Prostatic carcinoma, PTEN",
author = "Tamara Lotan and Asmus Heumann and Rico, {Sebastian Dwertmann} and Jessica Hicks and Kristen Lecksell and Christina Koop and Guido Sauter and Thorsten Schlomm and Ronald Simon",
year = "2017",
doi = "10.18632/oncotarget.19217",
language = "English (US)",
volume = "8",
pages = "65566--65576",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "39",

}

TY - JOUR

T1 - PTEN loss detection in prostate cancer

T2 - Comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort

AU - Lotan, Tamara

AU - Heumann, Asmus

AU - Rico, Sebastian Dwertmann

AU - Hicks, Jessica

AU - Lecksell, Kristen

AU - Koop, Christina

AU - Sauter, Guido

AU - Schlomm, Thorsten

AU - Simon, Ronald

PY - 2017

Y1 - 2017

N2 - PTEN deletion is an established prognostic biomarker in prostate cancer. We compared PTEN immunohistochemistry (IHC) and PTEN fluorescence in situ hybridization (FISH) in the largest existing radical prostatectomy cohort with clinical follow-up data. There was high concordance between IHC and FISH: 93% (3098/3330) of tumors with intact PTEN IHC showed absence of PTEN gene deletion and 66% (720/1087) of cases with PTEN protein loss by IHC showed PTEN gene deletion by FISH. 84% (447/533) of cases with PTEN homozygous gene deletion had PTEN protein loss by IHC. PTEN loss by IHC was associated with reduced PSA recurrence-free survival (RFS) in multivariable models (HR=1.3; 95% CI: 1.16-1.47). Among cases with either PTEN deletion or absence of PTEN deletion by FISH, PTEN loss by IHC was strongly associated with reduced RFS on univariable analysis (p=0.0005 and p < 0.0001 respectively). Among cases with intact PTEN by IHC, homozygous (p=0.04) but not heterozygous (p=0.10) PTEN gene deletion was weakly associated with reduced RFS. Among cases with PTEN loss by IHC, both homozygous (p=0.0044) and heterozygous (p=0.0017) PTEN gene deletion were associated with reduced RFS. These data support the utility of PTEN IHC and PTEN FISH as complementary screening tools for PTEN loss in prostate cancer.

AB - PTEN deletion is an established prognostic biomarker in prostate cancer. We compared PTEN immunohistochemistry (IHC) and PTEN fluorescence in situ hybridization (FISH) in the largest existing radical prostatectomy cohort with clinical follow-up data. There was high concordance between IHC and FISH: 93% (3098/3330) of tumors with intact PTEN IHC showed absence of PTEN gene deletion and 66% (720/1087) of cases with PTEN protein loss by IHC showed PTEN gene deletion by FISH. 84% (447/533) of cases with PTEN homozygous gene deletion had PTEN protein loss by IHC. PTEN loss by IHC was associated with reduced PSA recurrence-free survival (RFS) in multivariable models (HR=1.3; 95% CI: 1.16-1.47). Among cases with either PTEN deletion or absence of PTEN deletion by FISH, PTEN loss by IHC was strongly associated with reduced RFS on univariable analysis (p=0.0005 and p < 0.0001 respectively). Among cases with intact PTEN by IHC, homozygous (p=0.04) but not heterozygous (p=0.10) PTEN gene deletion was weakly associated with reduced RFS. Among cases with PTEN loss by IHC, both homozygous (p=0.0044) and heterozygous (p=0.0017) PTEN gene deletion were associated with reduced RFS. These data support the utility of PTEN IHC and PTEN FISH as complementary screening tools for PTEN loss in prostate cancer.

KW - Biomarker

KW - Fluorescence in situ hybridization

KW - Immunohistochemistry

KW - Prostatic carcinoma

KW - PTEN

UR - http://www.scopus.com/inward/record.url?scp=85029411033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029411033&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19217

DO - 10.18632/oncotarget.19217

M3 - Article

C2 - 29029453

AN - SCOPUS:85029411033

VL - 8

SP - 65566

EP - 65576

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 39

ER -